| Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 21719364 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Exenatide, a GLP-1 receptor agonist for adjuvant treatment of type 2 diabetes mellitus (T2DM), has been shown to be as effective as insulin glargine (IG) for reducing glycated hemoglobin levels combined with metformin or/and sulphonylureas. Exenatide is associated to weight reduction and a higher incidence of gastrointestinal adverse events. The objective of this study was to assess the cost-effectiveness of exenatide as compared to IG in obese patients with T2DM not achieving an adequate blood glucose control from the perspective of the Spanish healthcare system. METHODS: Pharmacoeconomic model inputs were obtained from an obese subpopulation (BMI ≥ 30 k/m(2)) of an international, randomized, controlled clinical trial comparing exenatide with IG in poorly controlled T2DM patients, and were supplemented with country-specific data. RESULTS: Exenatide was associated to improvements in life-years gained and quality-adjusted life years (QALYs) by 0.11 and 0.62 respectively versus IG. Direct costs were € 9,306 higher as compared to IG (€ 47,010 versus € 37,704, with increased pharmacy costs as the main driver). Exenatideís incremental cost-effectiveness ratio was € 15,068 per QALY gained versus IG. CONCLUSIONS: Exenatide was associated to greater clinical benefits and higher costs in obese T2DM patients as compared to IG. Considering a willingness-to-pay threshold of € 30,000 per QALY gained in the Spanish setting, exenatide represents an efficient option in comparison with IG. |
| | |
Authors:
|
Gordon Goodall; María Costi; Louise Timlin; Jesús Reviriego; José Antonio Sacristán; Jayne Smith-Palmer; Tatiana Dilla |
Related Documents
:
|
11979034 - Insulin treatment at onset of diabetes. leicester royal infirmary children's hospital, ... 123154 - Primary abdominal wall abscess diagnosed by ultrasound. 15152104 - Hereditary haemochromatosis. 9236564 - Diabetic muscular infarction. preventing morbidity by avoiding excisional biopsy. 2792574 - Deferoxamine therapy in high-ferritin diabetes. 9878384 - Watching amyloid fibrils grow by time-lapse atomic force microscopy. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-6-28 |
Journal Detail:
|
Title: Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion Volume: - ISSN: 1579-2021 ISO Abbreviation: - Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-7-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100886482 Medline TA: Endocrinol Nutr Country: - |
Other Details:
|
Languages: ENG; SPA Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2010 SEEN. Published by Elsevier Espana. All rights reserved. |
Affiliation:
|
IMS Health, Basilea, Suiza. |
Vernacular Title:
|
Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenoc...
Next Document: The continent ileostomy: An alternative to end ileostomy? Short and long-term results of a single in...